Overcoming Clinical Inertia

Slides:

Advertisements

Similar presentations

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Advertisements

The Value Of In-vitro Diagnostics Healthcare challenges in the 21 st century for governments & hospitals & how in-vitro diagnostics can contribute to overcoming.

COPD by the Guidelines.

Exploring Early Combination Therapy in PAH

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Stephen W. Waldo et al. JACC 2008;51:

Chronic Hepatitis C Virus Infection

Starting Strong: Initial Evaluation of the Patient With HCV

Optimizing Outcomes in Short Bowel Syndrome With IF

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Heart Rate, HF Admissions, and Readmissions

Cardiac Biomarkers.

Biomarkers in Heart Failure

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Cost Effectiveness and Optimal Outcomes in HF

Clyde W. Yancy et al. JACC 2017;70:

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

ACIP Recommended Vaccines for Adults – By Age

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Heart Failure Prevention: Mission Impossible?

An Update on PCSK9 Inhibitors

Treating HFrEF: Challenges Faced

Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.

Are We Closer to Personalized Medicine in MS?

Selected Highlights of the Latest Advances in PAH

Antithrombotic Protection in CAD and HF

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Advancing Acute Coronary Syndrome Assessment:

Improving Appropriate Access to PCSK9 Inhibitors

The Heart Failure Team Heart Failure Care Map First 24 hours.

Risk Stratification in CAD and PAD

Evaluating New Therapies in HF

G. Michael Felker et al. JCHF 2014;2:

Editorial Heart Failure Clinics

The Importance of Getting the Dose Right in HF

An Interprofessional Perspective on the Safe and Appropriate Use of Opioid Analgesics.

Using Heart Rate as a Biomarker in Clinical Practice.

Multidisciplinary Management of Hyperkalemia:

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Learning Objectives CMS Measures in HF: 30-day Hospital Readmission Rates.

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Intro: Biomarkers in RA

PAH-Related Morbidity as a Predictor of Mortality

New Strategies to Reduce HF Readmissions

Managing HF in Primary Care

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Program Goals Background: Anticoagulation in Patients With VTE.

Perspective on the Multidisciplinary Management of PAH

Assessing the Burden of Hyperkalemia

Breaking Down the Data in Hyperkalemia

Figure 3 Preventive strategies for CSA-AKI

Selecting Treatment Approaches in Hemophilia

Contemporary Considerations in Biomarker-Guided Therapy

An Update on PCSK9 Inhibitors

The Research Question Heart failure (HF) and atrial fibrillation (AF) frequently coexist and are associated with many adverse outcomes HF and AF share.

Assessing the Burden of Hyperkalemia

Championing Evidence-Based Care in Patients With Acute Low Back Pain

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

Managing HF in Primary Care

Prevent Pressure Injuries WORLD WIDE PRESSURE INJURY PREVENTION DAY

Key Data on Improving Outcomes in HF Patients

Rethinking Risk Stratification for Nonischemic HF:

Shared-Decision Making in Dyslipidemia

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Overcoming Clinical Inertia

Goals

Clinical Inertia

2017 ACC/AHA/HFSA HF Guidelines

Natriuretic Peptide Screening for Prevention of HF 2017 ACC/AHA/HFSA Recommendations

NT-proBNP and Prognosis After ADHF Treatment

Specificity/Sensitivity of BNP Thresholds

The Importance of Serial NP Measurements for Prognostication in Chronic HF

Clinical Scenario

Same-Day Urgent HF Clinics

Cardiac Biomarkers in HF Many Settings

Thinking Out of the Box

Biomarker Indications for Use 2017 ACC/AHA/HFSA Recommendations

PARADIGM-HF: Reduction of NT-proBNP to ≤ 1000 pg/mL Leads to Better Outcomes

NT-proBNP As a Motivator for Patients

GUIDE-IT Study Design

GUIDE-IT Outcomes

Patient With Non-HF Signal for Risk

STOP-HF Study Design

STOP-HF Outcomes

PONTIAC Study Design

PONTIAC Outcomes

It Takes a Team!

Interprofessional Strategies to Overcoming Barriers

Barriers to Guideline Implementation

Strategies for Implementing Guideline-Directed Management

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)